These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 38558290)

  • 21. Imaging-assisted anticancer nanotherapy.
    Dasgupta A; Biancacci I; Kiessling F; Lammers T
    Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming tumor microenvironment obstacles: Current approaches for boosting nanodrug delivery.
    Wang X; Zhang H; Chen X; Wu C; Ding K; Sun G; Luo Y; Xiang D
    Acta Biomater; 2023 Aug; 166():42-68. PubMed ID: 37257574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?
    Gawali P; Saraswat A; Bhide S; Gupta S; Patel K
    Nanomedicine (Lond); 2023 Jan; 18(2):169-190. PubMed ID: 37042320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical oncology: New targets for nanomedicine.
    Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
    Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
    Sun D; Zhou S; Gao W
    ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
    Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.
    Miao L; Lin CM; Huang L
    J Control Release; 2015 Dec; 219():192-204. PubMed ID: 26277065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
    Danhier F
    J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the tumor microenvironment with nanoparticles.
    Miao L; Huang L
    Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
    Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
    Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing Tumor Microenvironment Characteristics and Stratifying EPR with a Nanobubble Companion Nanoparticle via Contrast-Enhanced Ultrasound Imaging.
    Cooley MB; Wegierak D; Perera R; Abenojar EC; Nittayacharn PA; Berg FM; Kim Y; Kolios MC; Exner AA
    bioRxiv; 2023 Nov; ():. PubMed ID: 38045236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
    Bharali DJ; Mousa SA
    Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
    Shi Y; van der Meel R; Chen X; Lammers T
    Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery.
    Stapleton S; Jaffray D; Milosevic M
    Adv Drug Deliv Rev; 2017 Jan; 109():119-130. PubMed ID: 27262923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Platinum-based combination nanomedicines for cancer therapy.
    Li Y; Lin W
    Curr Opin Chem Biol; 2023 Jun; 74():102290. PubMed ID: 36989943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular imaging in nanomedicine - A developmental tool and a clinical necessity.
    Dearling JLJ; Packard AB
    J Control Release; 2017 Sep; 261():23-30. PubMed ID: 28624600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remodeling tumor microenvironment with nanomedicines.
    Martin JD; Miyazaki T; Cabral H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Nov; 13(6):e1730. PubMed ID: 34124849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.